<DOC>
	<DOCNO>NCT02372799</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability vilazodone compare placebo pediatric outpatient ( 7-17 year age ) major depressive disorder .</brief_summary>
	<brief_title>Safety Efficacy Vilazodone Pediatric Patients With Major Depressive Disorder ( VLZ-MD-22 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Male Female outpatient 717 year age Primary diagnosis Major Depressive Disorder ( MDD ) Children 's Depression Rating ScaleRevised ( CDRSR ) score 40 great Clinical Global ImpressionsSeverity ( CGIS ) score 4 great Current ( past 3 month ) principal Diagnostic Statistical Manual Mental Disorders , 4th edition , Text Revision ( DSMIVTR ) base diagnosis axis disorder major depressive disorder ( MDD ) primary focus treatment . History suicidal behavior , require precaution suicide Not generally healthy medical condition Seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>